This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/pubchem-compound/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/drugbank/
n13http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n18http://www.drugs.com/mtm/
n24http://linked.opendata.cz/resource/drugbank/patent/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/chemspider/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00992/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00992
rdf:type
n3:Drug
n3:description
Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.
n3:dosage
n10:271B4B23-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.medsafe.govt.nz/profs/Datasheet/m/Metvixcr.htm # Smits T, Moor AC: New aspects in photodynamic therapy of actinic keratoses. J Photochem Photobiol B. 2009 Sep 4;96(3):159-69. Epub 2009 Jun 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19592269
n3:group
approved
n3:indication
For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).
n3:manufacturer
n9:271B4B21-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00992 n13:DB00992
dcterms:title
Methyl aminolevulinate
adms:identifier
n12:Methyl_aminolevulinate n14:PA164784028 n16:157922 n19:46507004 n20:DB00992 n21:0299-6300-02 n22:724125 n23:138950
n3:mechanismOfAction
Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals.
n3:packager
n9:271B4B20-363D-11E5-9242-09173F13E4C5 n9:271B4B1F-363D-11E5-9242-09173F13E4C5
n3:patent
n24:6034267 n24:2215069
n3:synonym
Aminolevulinic acid methyl ester Methyl aminolevulinate 5-Aminolevulinic acid methyl ester Methyl delta-aminolevulinate
n3:toxicity
The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.
foaf:page
n18:methyl-aminolevulinate-topical.html
n3:IUPAC-Name
n4:271B4B28-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B2E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B2D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B2A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B2B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B2C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B26-363D-11E5-9242-09173F13E4C5 n4:271B4B3E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B27-363D-11E5-9242-09173F13E4C5 n4:271B4B24-363D-11E5-9242-09173F13E4C5 n4:271B4B3F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B25-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:L01XD03
n3:H-Bond-Acceptor-Count
n4:271B4B34-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B35-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B2F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B30-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B32-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B31-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B33-363D-11E5-9242-09173F13E4C5
n3:absorption
In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
33320-16-0
n3:containedIn
n15:271B4B22-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B3A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B3C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B3D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B39-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B38-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B3B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B29-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B36-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B37-363D-11E5-9242-09173F13E4C5